Lazard Asset Management
SRPT icon

Lazard Asset Management’s Sarepta Therapeutics SRPT Stock Holding History

Lazard Asset Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-445
Closed -$7.93K – 2279
2025
Q2 		$7K Sell
445
-4,340
-91% -$185K ﹤0.01% 2186
2025
Q1 		$304K Buy
4,785
+2,590
+118% +$273K ﹤0.01% 1528
2024
Q4 		$265K Sell
2,195
-78
-3% -$9.56K ﹤0.01% 1532
2024
Q3 		$283K Sell
2,273
-563
-20% -$77.8K ﹤0.01% 1528
2024
Q2 		$446K Buy
2,836
+299
+12% +$38.4K ﹤0.01% 1242
2024
Q1 		$328K Buy
2,537
+152
+6% +$18.6K ﹤0.01% 1157
2023
Q4 		$229K Buy
2,385
+60
+3% +$5.76K ﹤0.01% 1339
2023
Q3 		$280K Buy
2,325
+1,190
+105% +$135K ﹤0.01% 1279
2023
Q2 		$128K Buy
1,135
+455
+67% +$58.7K ﹤0.01% 1492
2023
Q1 		$93K Buy
680
+57
+9% +$7.39K ﹤0.01% 1557
2022
Q4 		$79K Sell
623
-1,090
-64% -$126K ﹤0.01% 1614
2022
Q3 		$188K Buy
1,713
+649
+61% +$65.4K ﹤0.01% 1280
2022
Q2 		$79K Buy
1,064
+41
+4% +$3.02K ﹤0.01% 1606
2022
Q1 		$79K Sell
1,023
-420
-29% -$32.2K ﹤0.01% 1509
2021
Q4 		$129K Sell
1,443
-315
-18% -$26.9K ﹤0.01% 1370
2021
Q3 		$162K Sell
1,758
-185
-10% -$14.3K ﹤0.01% 1321
2021
Q2 		$150K Sell
1,943
-4,568
-70% -$346K ﹤0.01% 1260
2021
Q1 		$485K Sell
6,511
-23,194
-78% -$2.14M ﹤0.01% 987
2020
Q4 		$5.06M Buy
29,705
+29,308
+7,382% +$4.34M 0.01% 654
2020
Q3 		$55K Sell
397
-155
-28% -$23.6K ﹤0.01% 1161
2020
Q2 		$88K Sell
552
-560
-50% -$76.2K ﹤0.01% 1051
2020
Q1 		$108K Buy
1,112
+1,088
+4,533% +$124K ﹤0.01% 987
2019
Q4 		$3K Sell
24
-150
-86% -$15.1K ﹤0.01% 1460
2019
Q3 		$13K Buy
+174
New +$20.5K ﹤0.01% 1234
2019
Q1 		– Sell
-1,000
Closed -$109K – 1199
2018
Q4 		$109K Hold
1,000
– – ﹤0.01% 909
2018
Q3 		$161K Sell
1,000
-6,370
-86% -$871K ﹤0.01% 893
2018
Q2 		$973K Buy
+7,370
New +$695K ﹤0.01% 728

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Lazard Asset Management's SRPT Position: Q3 2025 in Review

Lazard Asset Management sold out of Sarepta Therapeutics (SRPT) in Q3 2025, closing a stake of 445 shares — an estimated $7.93K sold.

Lazard Asset Management first reported a position in SRPT in Q2 2018 and held it in 27 quarters. The position peaked at $5.06M in Q4 2020. 319 funds tracked by Wall St. Rank hold SRPT as of Q3 2025.

  • Lazard Asset Management reported no remaining Sarepta Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Lazard Asset Management sold 445 Sarepta Therapeutics shares in Q3 2025, an estimated $7.93K.
  • Lazard Asset Management first reported a position in Sarepta Therapeutics in Q2 2018 and held it in 27 quarters.
  • Lazard Asset Management's Sarepta Therapeutics position peaked at $5.06M in Q4 2020.
  • 319 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2025.

Based on Lazard Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.